moxifloxacin has been researched along with antofloxacin in 3 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (antofloxacin) | Trials (antofloxacin) | Recent Studies (post-2010) (antofloxacin) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 26 | 13 | 14 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Qi, HM; Wei, MJ; Zhang, L; Zhao, CY | 1 |
| Chen, S; Dong, L; Huang, H; Köser, CU; Moradigaravand, D; Parkhill, J; Peacock, SJ; Schön, T; Shang, Y; Wang, G; Wei, G; Yu, X | 1 |
| He, YC; Huang, JH; Li, LJ; Li, YF; Liang, LY; Wang, K; Xu, FY; Yang, J; Zheng, QS | 1 |
1 trial(s) available for moxifloxacin and antofloxacin
| Article | Year |
|---|---|
Relationship between antofloxacin concentration and QT prolongation and estimation of the possible false-positive rate.
Topics: Adult; Anti-Bacterial Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; False Positive Reactions; Female; Healthy Volunteers; Heart Rate; Humans; Long QT Syndrome; Male; Models, Statistical; Moxifloxacin; Ofloxacin; Young Adult | 2020 |
2 other study(ies) available for moxifloxacin and antofloxacin
| Article | Year |
|---|---|
Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes.
Topics: Animals; Anti-Infective Agents; Aryl Hydrocarbon Hydroxylases; Aza Compounds; Ciprofloxacin; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C9; Fluoroquinolones; Gatifloxacin; Humans; Isoenzymes; Levofloxacin; Microsomes, Liver; Molecular Structure; Moxifloxacin; Ofloxacin; Quinolines; Reproducibility of Results | 2008 |
Wild-Type and Non-Wild-Type Mycobacterium tuberculosis MIC Distributions for the Novel Fluoroquinolone Antofloxacin Compared with Those for Ofloxacin, Levofloxacin, and Moxifloxacin.
Topics: Antitubercular Agents; China; DNA Gyrase; Drug Dosage Calculations; Drug Resistance, Bacterial; Fluoroquinolones; Gene Expression; Genotype; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Tuberculosis, Pulmonary | 2016 |